Hormontherapie in der Peri- und Postmenopause

Abstract

The recently published 18-year-follow-up of the WHI-study might resolve the long-standing dispute about hormone therapy, possibly reconciling the opposing parties attributing life-threatening risks to either the administration or the withholding of hormone therapy. 16 608 women without hysterectomy had taken either combined hormone therapy with estrogen and progestin or placebo for an average of 5.2 years, while 10 739 women after hysterectomy (and bilateral ovarectomy in 40 %) had taken either estrogen therapy alone or placebo for an average of 7 years. 7489 deaths were recorded until 2014. Over both studies, mortality was 27.1 % after hormone therapy and 27.6 % after placebo. New findings on perimenopause can help towards phase-adapted and complaint-targeted hormone therapy in the future.

2002 und 2004 wurden die beiden Women’s-Health-Initiative-Studien, welche die Hormontherapie (HT) bei Frauen in der Peri- und Postmenopause untersuchten, abgebrochen – seither war die HT umstritten. Die jetzt publizierten 18-Jahres-Daten der beiden Studien könnten diesen Streit beenden. Dieser Beitrag fasst neue Erkenntnisse zu den Phasen der Perimenopause und den aktuellen Wissensstand zu Anwendung, Nutzen und Risiken der HT zusammen.

Schlüsselwörter

Perimenopause - Postmenopause - Hormontherapie - Östrogen - Gestagen

Key words

perimenopause - postmenopause - hormone therapy - estrogen - progestin

• Literatur

• 1 Harlow SD, Gass M, Hall JE. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. JCEM 2012; 97: 1159-1168
• 2 Sarri G, Davies M, Lumsden MA. Guideline Development Group. . Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015; 351: h5746
• 3 Avis NE, Crawford SL, Greendale G. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-539
• 4 Stuenkel CA, Davis SR, Gompel A. et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 3975-4011
• 5 Santen RJ, Stuenkel CA, Davis SR. et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab 2017; 102: 3647-3661
• 6 [No authors listed]. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22: 1155-1172 ; quiz 1173–1174
• 7 Santen RJ, Allred DC, Ardoin SP. et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95 (01) s1-s66
• 8 Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms – a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012; 19: 886-893
• 9 Rossouw JE, Anderson GL, Prentice RL. Writing Group for the Women’s Health Initiative Investigators. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
• 10 Anderson GL, Limacher M, Assaf AR. Women’s Health Initiative Steering Committee. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712
• 11 Prior JC, Seifert-Klauss VR, Giustini D. et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact 2017; 17: 146-154
• 12 Manson JE, Chlebowski RT, Stefanick ML. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-1368
• 13 Manson JE, Aragaki AK, Rossouw JE. et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative randomized trials. JAMA 2017; 318: 927-938
• 14 Seifert-Klauss V, Kiechle M. Neue Erkenntnisse zur Hormonersatztherapie. Bayerisches Ärzteblatt 2006; 11: 542-546
• 15 Laughlin-Tommaso SK, Khan Z, Weaver AL. et al. Cardiovascular risk factors and diseases in women undergoing hysterectomy with ovarian conservation. Menopause 2016; 23: 121-128
• 16 Matthews KA, Gibson CJ, El Khoudary SR. et al. Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: Study of Women’s Health Across the Nation. J Am Coll Cardiol 2013; 62: 191-200
• 17 Laliberté F, Dea K, Duh MS. et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18: 1052-1059
• 18 Olié V, Plu-Bureau G, Conard J. et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011; 18: 488-493
• 19 Fournier A, Berrino F, Riboli E. et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448-454
• 20 Doherty JA, Cushing-Haugen KL, Saltzman BS. et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007; 197: 139.e1–7
• 21 S3-Leitlinie Hormontherapie in der Peri- und Postmenopause. AWMF-Registernummer 015 – 062. September 2009. Im Internet: http://www.awmf.org/leitlinien/detail/ll/015-062.html ; Stand: 14.08.2018
• 22 Gupte A, Pownall H, Hamilton D. Estrogen: An emerging regulator of insulin action and mitochondrial function. J Diabetes Res 2015; 2015: 916585
• 23 Mauvais-Jarvis F, Manon JE, Stevenson JC. et al. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocr Rev 2017; 38 (03) 173-188